Veracode Opens New Office in Prague With Accion Labs
Veracode, a leading global provider of intelligent software security solutions, today announced the official opening of its new engineering facility in Prague, Czech Republic (Prague Engineering Centre). The center has been built in partnership with Accion Labs, a global provider of end-to-end software product engineering services, and will leverage expanded international support to deliver Veracode’s market-leading software security solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230321005027/en/
Veracode office in Prague (Photo: Business Wire)
As Veracode continues to expand its global footprint, most recently with the acquisition of Crashtest Security’s dynamic analysis solution in Germany and the launch of its European cloud-based instance, the new engineering center of excellence will enable the growth of Veracode’s European Research & Development capabilities. The operation will drive greater velocity of product development and innovation to the market.
Brian Roche, Chief Product Officer at Veracode: “For nearly two decades, Veracode has empowered customers to secure more than 100 trillion lines of code. Today’s opening of our new engineering facility in Prague is a landmark moment for us as we continue our global expansion and support to build on this momentum. We are thrilled to welcome our new highly skilled engineers to the growing Research & Development team, who will increase our innovation capacity and deliver market-differentiating value for customers everywhere.”
Through a single, centralized platform that offers comprehensive visibility of security posture using a comprehensive set of testing solutions, Veracode secures code across languages in open-source, legacy, and cloud-native applications. The Veracode Continuous Software Security Platform automatically finds and fixes vulnerabilities across the software development lifecycle, delivering ease of use, speed, and actionable results for security teams, developers, and Boards.
Tom Collins, Chief Operating Officer at Accion Labs added: “The Prague center accelerates our strategic commitment to the EU, and we are thrilled to be partnering with Veracode and bringing together a best-in-class engineering center.”
The office opening in Prague comes shortly after Veracode’s head office in Burlington, MA, was named a “Top Place to Work in Massachusetts” by the Boston Globe and a “2023 Top Workplaces USA” by Energage.
The new engineering center in Prague officially opens today. Open positions are currently available here.
About Veracode -www.veracode.com
Veracode is a leading AppSec partner for creating secure software, reducing the risk of security breach, and increasing security and development teams’ productivity. As a result, companies using Veracode can move their business, and the world, forward. With its combination of process automation, integrations, speed, and responsiveness, Veracode helps companies get accurate and reliable results to focus their efforts on fixing, not just finding, potential vulnerabilities. Learn more at www.veracode.com, on the Veracode blog, on LinkedIn, and on Twitter.
About Accion Labs - www.accionlabs.com
Accion’s core purpose is to impact lives by transforming businesses through innovation. Spread over 22 global offices, Accion has an engineering headcount of more than 5,000 employees. Accion engages with its clients in a range of collaborative, white-box engagement models that include extended teams, and turn-key projects. Accion holds the expertise in building new products and re-engineering legacy products using state of the art technologies and innovation. Led by an entrepreneurial leadership team that focuses on execution, outcome, and continuous learning, Accion Labs has been recognized as one of Pittsburgh’s fastest-growing companies by the Pittsburgh Business Times and as a leader in innovation by Smart Business Magazine. Read more about Accion at www.accionlabs.com / LinkedIn / Prague Engineering Centre
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230321005027/en/
Contact information
Veracode –
Katy Gwilliam
kgwilliam@veracode.com
Accion Labs –
Janki Sampat
Janki.sampat@accionlabs.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 10:53:00 CET | Press Release
NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press Release
Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeking future-ready solutions. At the core of this strategy is Regnology Risk Hub (RRiskHub), an integrated solution designed to deliver a single
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press Release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press Release
Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at week 16, with a significantly greater PASI 75 response rate seen as early as week 4 and continuing to increase through week 24. The studies also met all 44 ranked secondary endpoints, including PASI 90, PASI 100 and sPGA 0 against placebo and apremilast, showing the potential of a convenient once-daily pill to deliver complete skin clearance for patients with PsO. “People living with psoriasis continue to seek safe, effective and fast-acting oral therap
DATROWAY ® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press Release
The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use. The application is based on data from the TROPION-Breast02 phase 3 trial presented in a late-breaking proffered paper session at the 2025 European Society for Medical Oncology (#ESMO25) Congress. In the trial, DATROWAY demonstrated statistically significant and clinical
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom